Neuregulin

Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction

Retrieved on: 
Wednesday, September 7, 2022

Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.

Key Points: 
  • Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.
  • We are also excited to now be recruiting for the first clinical trial with our IL15-CTLA4 antibody fusion, JK08, and we expect to share initial data in 2023.
  • JK08 was designed based on clinical studies from both individual molecules, which together portend synergistic effects in an antibody fusion construct.
  • A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 13) in Patients With Systolic Dysfunction and Heart Failure.

Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling

Retrieved on: 
Saturday, April 10, 2021

As in prior analysis in lung and ovarian NRG1 fusion PDX models, the pan-ERBB inhibitor afatinib was used as an active control in this pancreatic PDX model.

Key Points: 
  • As in prior analysis in lung and ovarian NRG1 fusion PDX models, the pan-ERBB inhibitor afatinib was used as an active control in this pancreatic PDX model.
  • NRG1fusions have been identified in a variety of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, neuroendocrine, cholangiocarcinomas, and sarcomas.
  • The NRG1 gene fusion is a rare genomic alteration that combines NRG1 with another partner protein to create chimeric NRG1 "fusion proteins".
  • In preclinical experiments, seribantumab prevented the activation of HER3 signaling in cells that harbor an NRG1 gene fusion.

Merus Announces Financial Results for the Second Quarter and Provides Business Update

Retrieved on: 
Thursday, August 6, 2020

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and TriclonicsTM), today announced financial results for the second quarter that ended June30, 2020, and provided a business update.

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and TriclonicsTM), today announced financial results for the second quarter that ended June30, 2020, and provided a business update.
  • We are pleased to report several updates and progress with our business this quarter, said Bill Lundberg, M.D., President, Chief Executive Officer and Principal Financial Officer of Merus.
  • We look forward to providing a substantive clinical update on zenocutuzumab (Zeno) for neuregulin 1 (NRG1) fusion cancers by year end.
  • The Company ended the second quarter with cash, cash equivalents and marketable securities of $197.4 million compared to $241.8 million at December 31, 2019.

Merus Appoints Andrew Joe, M.D., as Chief Medical Officer

Retrieved on: 
Monday, July 27, 2020

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the appointment of Andrew Joe, M.D., as Chief Medical Officer.

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the appointment of Andrew Joe, M.D., as Chief Medical Officer.
  • Andrew is an accomplished R&D leader, and he will be instrumental in advancing our clinical pipeline of multispecific antibodies, including our lead program, Zenocutuzumab (Zeno), for neuregulin 1 (NRG1) fusion cancers, said Bill Lundberg, M.D., President, Chief Executive Officer and Principal Financial Officer of Merus.
  • Dr. Joe will oversee all clinical and regulatory strategy and activities at Merus.
  • ZELBORAF is a registered trademark of Genentech Inc.
    Merus Investor and Media Inquiries: Jillian Connell Merus N.V. Investor Relations and Corporate Communications 617-955-4716 [email protected]

Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients

Retrieved on: 
Monday, July 13, 2020

and IRVING, Texas, July 13, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics) and Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a collaboration to detect neuregulin 1 (NRG1) fusions in cancer patients.

Key Points: 
  • and IRVING, Texas, July 13, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics) and Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a collaboration to detect neuregulin 1 (NRG1) fusions in cancer patients.
  • We are pleased to collaborate with Merus and to identify patients with NRG1 fusions, said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences.
  • The NRG1 gene fusion is a rare, powerful driver of cancer cell growth found in lung, pancreatic and other solid tumor types.
  • The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.